Natriuretic Peptide

Purpose:
Natriuretic peptide testing – B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-Pro BNP) is an important tool for rapidly assessing adults presenting with new suspected acute heart failure.

NICE Clinical guideline [CG187], 2021: Acute heart failure: diagnosis and management
1.2.2 In people presenting with new suspected acute heart failure, use a single measurement of serum natriuretic peptides BNP or NT-Pro BNP) and the following thresholds to rule out the diagnosis of heart failure:

BNP less than 100 ng/litre
NT-Pro BNP less than 300 ng/litre.

1.2.3 In people presenting with new suspected acute heart failure with raised natriuretic peptide levels (see recommendation 1.2.2), perform transthoracic Doppler 2D echocardiography to establish the presence or absence of cardiac abnormalities.

NICE guideline [NG106], 2018 Chronic heart failure in adults: diagnosis and management also recommend the measurement of (NT-Pro BNP) in people with suspected chronic heart failure as part of the diagnostic pathway.

NT-Pro BNP conc.	Recommendation
< 400 ng/L	Heart failure not confirmed consider other causes of symptoms
400 – 2000ng/L	Refer for special clinical assessment including ECHO within 6 weeks
> 2000 ng/L	Urgent refer for special clinical assessment including ECHO within 2 weeks

Consider measuring NT-Pro BNP as part of a treatment optimisation protocol only in a specialist care setting for people aged under 75 who have heart failure with reduced ejection fraction and an eGFR above 60ml/min/1.73m2.

Scope:
Three samples covering the appropriate physiological and pathological range including challenging samples near the diagnostic thresholds are distributed bimonthly for the assessment of NT-Pro BNP.

The base material is human lithium heparin plasma to reflect the preferred sample type used for patient testing. The samples consist of a panel of linearly related samples produced from donations from healthy volunteers spiked with recombinant human NT-Pro BNP, with the addition of protease inhibitors to improve stability.

Surrogate, clinically appropriate linear panels suitable for both Laboratory and PoCT analysers are provided. The programmes assess both laboratory and method performance, including bias, within and between batch imprecision and linearity.